• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患有间质性肺疾病的肺癌患者行楔形切除术的安全性和可行性:来自静冈多中心登记处的真实世界数据

Safety and Feasibility of Wedge Resection in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease: Real-World Data from Multicenter, Shizuoka Registry.

作者信息

Sekihara Keigo, Takei Kensuke, Homma Koshi, Shibata Motohisa, Funai Kazuhito

机构信息

Division of Surgery First, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo Ward, Hamamatsu 431-3192, Japan.

出版信息

J Clin Med. 2025 Aug 13;14(16):5724. doi: 10.3390/jcm14165724.

DOI:10.3390/jcm14165724
PMID:40869550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12386954/
Abstract

Acute exacerbation of interstitial lung disease (AE-ILD) is a life-threatening complication in lung cancer patients with pre-existing ILD. Anatomical resection is recognized as a significant risk factor for AE-ILD. We investigated the safety and feasibility of wedge resection in lung cancer patients with ILD. This retrospective study analyzed clinical stage IA-IIIA primary lung cancer patients with ILD, as recorded in the Shizuoka Registry across eight institutions from January 2019 to May 2023. Patients were categorized into a wedge resection group (WG) and an anatomical resection group (AG), which included segmentectomy, lobectomy, and bilobectomy. Perioperative outcomes were compared between the groups. The WG comprised 36 patients, while the AG included 81. The WG had significantly older patients (77 vs. 72 years, < 0.01) and smaller tumors (18 vs. 24 mm, < 0.01). Wedge resection was associated with shorter operative time (100 vs. 205 min, < 0.01) and less blood loss (5 vs. 30 mL, = 0.02). The incidence of postoperative complications did not differ significantly ( = 0.84). AE-ILD occurred in three patients (8%) in the WG and four patients (4%) in the AG. Perioperative mortality was 0% in the WG and 2% in the AG; both deaths were due to AE-ILD. Marginal recurrence was observed in four patients (11%) in the WG. Although AE-ILD incidence was higher, no deaths due to IP-AE were observed in the WG. While wedge resection cannot completely prevent postoperative AE-ILD, it may reduce perioperative mortality in lung cancer patients with ILD.

摘要

间质性肺疾病急性加重(AE-ILD)是患有基础ILD的肺癌患者的一种危及生命的并发症。解剖性切除被认为是AE-ILD的一个重要危险因素。我们研究了楔形切除在患有ILD的肺癌患者中的安全性和可行性。这项回顾性研究分析了2019年1月至2023年5月静冈登记处记录的八家机构中临床分期为IA-IIIA期的原发性肺癌合并ILD患者。患者被分为楔形切除组(WG)和解剖性切除组(AG),后者包括段切除术、肺叶切除术和双肺叶切除术。比较了两组的围手术期结果。WG组有36例患者,而AG组有81例。WG组患者年龄显著更大(77岁对72岁,<0.01)且肿瘤更小(18mm对24mm,<0.01)。楔形切除与手术时间更短(100分钟对205分钟,<0.01)和失血量更少(5mL对30mL,=0.02)相关。术后并发症发生率无显著差异(=0.84)。WG组有3例患者(8%)发生AE-ILD,AG组有4例患者(4%)发生。WG组围手术期死亡率为0%,AG组为2%;两例死亡均因AE-ILD。WG组有4例患者(11%)观察到边缘复发。虽然AE-ILD发生率更高,但WG组未观察到因IP-AE导致的死亡。虽然楔形切除不能完全预防术后AE-ILD,但它可能降低患有ILD的肺癌患者的围手术期死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/c4a7322591f7/jcm-14-05724-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/8fa0dd6930c0/jcm-14-05724-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/63927a3311a3/jcm-14-05724-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/c4a7322591f7/jcm-14-05724-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/8fa0dd6930c0/jcm-14-05724-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/63927a3311a3/jcm-14-05724-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72a1/12386954/c4a7322591f7/jcm-14-05724-g003.jpg

相似文献

1
Safety and Feasibility of Wedge Resection in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease: Real-World Data from Multicenter, Shizuoka Registry.患有间质性肺疾病的肺癌患者行楔形切除术的安全性和可行性:来自静冈多中心登记处的真实世界数据
J Clin Med. 2025 Aug 13;14(16):5724. doi: 10.3390/jcm14165724.
2
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者,在重建下肢节段性切除时,采用带血管游离腓骨移植来增强照射后的自体骨移植,其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当?
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
5
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.环磷酰胺用于治疗结缔组织病相关的间质性肺疾病。
Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2.
6
and DL predicting general complications but not prolonged air leaks in pulmonary segmentectomy.并且深度学习预测肺段切除术中的一般并发症,但不能预测长时间漏气。
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251341777. doi: 10.1177/17534666251341777. Epub 2025 Jul 7.
7
Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.实体恶性肿瘤患者间质性肺疾病的流行病学和病因学:一项系统文献综述
Future Oncol. 2025 Sep 1:1-11. doi: 10.1080/14796694.2025.2550928.
8
The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.样本采集部位和采集程序对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染鉴定的影响。
Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780.
9
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
10
Pulmonary rehabilitation for interstitial lung disease.间质性肺疾病的肺康复治疗。
Cochrane Database Syst Rev. 2021 Feb 1;2(2):CD006322. doi: 10.1002/14651858.CD006322.pub4.

本文引用的文献

1
Safe surgical lung biopsy in the diagnosis of interstitial lung disease under strict patient selection.
Respir Investig. 2025 Jan;63(1):81-85. doi: 10.1016/j.resinv.2024.11.018. Epub 2024 Dec 7.
2
Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.合并呼吸系统疾病的非小细胞肺癌的治疗策略;间质性肺炎、慢性阻塞性肺疾病和肺结核
Cancers (Basel). 2024 Apr 29;16(9):1734. doi: 10.3390/cancers16091734.
3
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
4
Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia.单次分割碳离子放疗对合并间质性肺炎的早期肺癌的安全性和有效性
Cancers (Basel). 2024 Jan 29;16(3):562. doi: 10.3390/cancers16030562.
5
Thoracic and cardiovascular surgeries in Japan during 2020 : Annual report by the Japanese Association for Thoracic Surgery.2020年日本胸心血管外科手术:日本胸外科学会年度报告
Gen Thorac Cardiovasc Surg. 2024 Jan;72(1):61-94. doi: 10.1007/s11748-023-01979-8. Epub 2023 Nov 28.
6
Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease.肺癌合并间质性肺疾病患者的治疗与预后
Cancers (Basel). 2023 Jul 30;15(15):3876. doi: 10.3390/cancers15153876.
7
Stereotactic body radiation therapy for stage I medically operable non-small cell lung cancer.立体定向体部放疗治疗 I 期可手术非小细胞肺癌。
Sci Rep. 2023 Jun 27;13(1):10384. doi: 10.1038/s41598-023-37643-7.
8
Overall Survival with Osimertinib in Resected -Mutated NSCLC.奥希替尼治疗可切除突变型 NSCLC 的总生存期。
N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.
9
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.肺段或亚肺叶切除术治疗外周型ⅠA 期非小细胞肺癌。
N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083.
10
Surgical lung biopsy for interstitial lung diseases-a single center study of 129 patients.间质性肺疾病的外科肺活检——一项针对129例患者的单中心研究
J Thorac Dis. 2022 Jun;14(6):1972-1979. doi: 10.21037/jtd-21-1773.